

Product News

Lonza Launches Worldwide Licensing Options for Its Chemical Microreaction Technology

- **The Microreaction Technology (MRT) platform now offers research and commercial licensing options, allowing customers access to Lonza's chemical technology for internal development and manufacture**
- **The MRT Research Evaluation Agreement includes access to Lonza's proprietary operating procedures, process protocols and algorithms for early candidate assessment using the FlowPlate® Microreactor Platform**
- **A manufacturing license enables customers to manufacture a single product at their own facility**

Basel, Switzerland, 25 September 2014 – Lonza, a world leader in the development of flow chemistry processes for the manufacture of fine chemicals and APIs, announced today two new licensing options for its Microreaction Technology (MRT) Platform. This is the latest addition to our award-winning MRT offering, which includes Lonza's FlowPlate® Reactors. The reactors are available in four sizes, with innovative milli- and micro-channel designs. This technology has already been used to develop multiple small-molecule and peptide products.

“Our customers will benefit from these chemical technology licenses for their product development and manufacturing needs,” said Karen Fallen, Vice President of Licensing, Lonza Custom Development Services. “The new licensing options will enable our customers to evaluate the MRT Platform with increased control and oversight of their product throughout its lifecycle.”

The key benefits of the new Research Evaluation Agreement (REA) include access to Lonza's extensive know-how and patents in microreaction technology, in addition to the FlowPlate® Reactors. Customers will receive the FlowPlate® Lab platform processes for set-up, scale-up, and system operation, along with world-class technical support. These platform protocols will support faster initial process development and ultimately shorten the time to large-scale production.

Product News

As compared with traditional chemical-batch processing, the increased reaction specificity achieved with Lonza's Microreaction Technology has been shown to result in better yields, therefore ultimately reducing cost of goods. Additionally, the MRT platform provides options for fast, flexible scale-up contributing to shortened development timelines for a significant advantage in the development and manufacture of drug candidates.

For more information on the Lonza's Microreaction Technology and licensing options, please visit us at www.lonza.com/mrt.

About Lonza

Lonza is one of the world's leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. We harness science and technology to create products that support safer and healthier living and that enhance the overall quality of life.

Not only are we a custom manufacturer and developer, Lonza also offers services and products ranging from active pharmaceutical ingredients and stem-cell therapies to drinking water sanitizers, from the vitamin B compounds and organic personal care ingredients to agricultural products, and from industrial preservatives to microbial control solutions that combat dangerous viruses, bacteria and other pathogens.

Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 40 major manufacturing and R&D facilities and approximately 10,000 employees worldwide. The company generated sales of about CHF 3.6 billion in 2013 and is organized into two market-focused segments: Pharma&Biotech and Specialty Ingredients. Further information can be found at www.lonza.com.

Further Information

Lonza Group Ltd
VP, Licensing and Technology
Custom Development Services
Karen Fallen
Tel +44 17 5371 6585
karen.fallen@lonza.com

Lonza Group Ltd
Chemistry Business Development
Custom Development Services
Stéphane Varray
Tel +41 27 948 6918
stephane.varray@lonza.com

Lonza Group Ltd
Head External Communications
Constance Ward
Tel +41 61 361 8840
Fax +41 61 316 9840
constance.ward@lonza.com

Additional Information and Disclaimer

Lonza Group Ltd is headquartered in Basel, Switzerland, and is listed on the SIX Swiss Exchange and secondary listed on the Singapore Exchange Securities Trading Limited ("SGX-ST"). Lonza Group Ltd is not subject to the SGX-ST's continuing

Product News

listing requirements. Lonza Group Ltd is subject to the listing rules of the SIX Swiss Exchange, which does not have specific requirements equivalent to the listing rules of the SGX-ST for interested person transactions, acquisition and realizations and delisting.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.